Search NASA⌕ Search

Engineering topics

Sergent, Francois

Publications and source records attributed to Sergent, Francois.

The Octavius1500 2D ion chamber array and its associated phantoms: Dosimetric characterization of a new prototype

Purpose: The purpose of the study is to characterize the prototype of the new Octavius1500 (PTW, Freiburg, Germany) 2D ion chamber array, covering its use in different phantom setups, from the most basic solid water sandwich setup to the more complex cylindrical Octavius{sup ®} 4D (Oct4D) (PTW) phantom/detector combination. The new detector houses nearly twice the amount of ion chambers as its predecessors (Seven29 and Octavius729), thereby tackling one of the most important limitations of ion chamber (or diode) arrays, namely the limited detector density. The 0.06 cm{sup 3} cubic ion chambers are now arranged in a checkerboard pattern, leaving no lines (neither longitudinally nor laterally) without detectors. Methods: All measurements were performed on a dual energy (6 MV and 18 MV) iX Clinac (Varian Medical Systems, Palo Alto, CA) and all calculations were done in the Eclipse treatment planning system (Varian) with the Anisotropic Analytical Algorithm. First, the basic characteristics of the 2D array, such as measurement stability, dose rate dependence and dose linearity were investigated in the solid water sandwich setup. Second, the directional dependence was assessed to allow the evaluation of the new Octavius2D phantom (Oct2D{sup 1500}) for planar verification measurements of composite plans. Third, measurements were performed in the Oct4D phantom to evaluate the impact of the increased detector density on the accuracy of the volumetric dose reconstruction. Results: While showing equally good dose linearity and dose rate independence, the Octavius1500 outperforms the previous models because of its instantaneous measurement stability and its twofold active area coverage. Orthogonal field-by-field measurements immediately benefit from the increased detector density. The 3.9 cm wide compensation cavity in the new Oct2D{sup 1500} phantom prototype adequately corrects for directional dependence from the rear, resulting in good agreement within the target dose. Discrepancies may arise towards the sides of the array because of uncompensated lateral beam incidence. The beneficial impact of the detector density is most prominent in the Oct4D system, for which the average pass rate (PR) is now nearly 100% (99.31 ± 0.37) when using gamma criteria of 2%G,2 mm (10% dose threshold). In search of gamma analysis criteria that are not too lenient to detect possibly relevant deviations, the authors conclude that for our radiotherapy environment, the authors choose to adopt 3%L,3 mm PR97% (threshold 10%) criteria for the Oct2D{sup 1500}/Octavius1500 system and 2%L,3 mm PR97% (threshold 10%) for the Oct4D/Octavius1500 system. These are first line pass/check criteria and plans that fail are not necessarily rejected, but submitted to a more detailed investigation. Conclusions: When irradiated from the front, the Octavius1500 array has two main advantages over its 729 predecessors: its instantaneous measurement stability and-–most importantly—its twofold detector density. In the Oct2D1500 phantom, these advantages are counterbalanced by the more pronounced directional dependence. The measurement-based 3D dose reconstruction in the Oct4D system, however, benefits considerably from the higher detector density in the checkerboard panel design.

07 ISOTOPE AND RADIATION SOURCES↗

Implementing RapidArc into clinical routine: A comprehensive program from machine QA to TPS validation and patient QA

Purpose: With the increased commercial availability of intensity modulated arc therapy (IMAT) comes the need for comprehensive QA programs, covering the different aspects of this newly available technology. This manuscript proposes such a program for the RapidArc (RA) (Varian Medical Systems, Palo Alto) IMAT solution. Methods: The program was developed and tested out for a Millennium120 MLC on iX Clinacs and a HighDefinition MLC on a Novalis TX, using a variety of measurement equipment including Gafchromic film, 2D ion chamber arrays (Seven29 and StarCheck, PTW, Freiburg, Germany) with inclinometer and Octavius phantom, the Delta4 systam (ScandiDos, Uppsala, Sweden) and the portal imager (EPID). First, a number of complementary machine QA tests were developed to monitor the correct interplay between the accelerating/decelerating gantry, the variable dose rate and the MLC position, straining the delivery to the maximum allowed limits. Second, a systematic approach to the validation of the dose calculation for RA was adopted, starting with static gantry and RA specific static MLC shapes and gradually moving to dynamic gantry, dynamic MLC shapes. RA plans were then optimized on a series of artificial structures created within the homogeneous Octavius phantom and within a heterogeneous lung phantom. These served the double purpose of testing the behavior of the optimization algorithm (PRO) as well as the precision of the forward dose calculation. Finally, patient QA on a series of clinical cases was performed with different methods. In addition to the well established in-phantom QA, we evaluated the portal dosimetry solution within the Varian approach. Results: For routine machine QA, the ''Snooker Cue'' test on the EPID proved to be the most sensitive to overall problem detection. It is also the most practical one. The ''Twinkle'' and ''Sunrise'' tests were useful to obtain well differentiated information on the individual treatment delivery components. The AAA8.9 dose calculations showed excellent agreement with all corresponding measurements, except in areas where the 2.5 mm fixed fluence resolution was insufficient to accurately model the tongue and groove effect or the dose through nearly closed opposing leafs. Such cases benefited from the increased fluence resolution in AAA10.0. In the clinical RA fields, these effects were smeared out spatially and the impact of the fluence resolution was considerably less pronounced. The RA plans on the artificial structure sets demonstrated some interesting characteristics of the PRO8.9 optimizer, such as a sometimes unexpected dependence on the collimator rotation and a suboptimal coverage of targets within lung tissue. Although the portal dosimetry was successfully validated, we are reluctant to use it as a sole means of patient QA as long as no gantry angle information is embedded. Conclusions: The all-in validation program allows a systematic approach in monitoring the different levels of RA treatments. With the systematic approach comes a better understanding of both the capabilities and the limits of the used solution. The program can be useful for implementation, but also for the validation of major upgrades.

46 INSTRUMENTATION RELATED TO NUCLEAR SCIENCE AND ↗